Amyris (AMRS) Announces Biossance Launches The Illuminator
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Biossance™ Launches The Illuminator ─ A Clinically Proven, Weightless Eye Gel
August 17, 2016 8:30 AM EDTEMERYVILLE, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Biossance, the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (Nasdaq: AMRS), has introduced The Illuminator, a dual peptide, weightless eye gel with exceptional clinical results.
... More
